Polaryx Therapeutics, Inc. (PLYX)
1.61
+0.01
(+0.62%)
USD |
NASDAQ |
Nov 18, 16:00
1.61
0.00 (0.00%)
After-Hours: 20:00
Polaryx Therapeutics Debt to Equity Ratio : 0.00 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.00 |
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| Date | Value |
|---|---|
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Cocrystal Pharma, Inc. | 0.4699 |
| CNBX Pharmaceuticals, Inc. | -0.4388 |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 0.0148 |
| Fulcrum Therapeutics, Inc. | 0.0226 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 8.61M |
| Total Liabilities (Quarterly) | 0.999M |
| Shareholders Equity (Quarterly) | 7.611M |
| Current Ratio | 8.619 |